C. Pereira

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in PortugalCost-effectiveness of new oral anticoagulants in Portuguese atrial fibrillation patients

D. Caldeira, F. Fiorentino, M. Gouveia, 2015 .

Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal

H. Marques, C. Sottomayor, C. Pereira, 2016 .

Cost and Burden of Female Breast Cancer in Portugal

F. Fiorentino, M. Gouveia, João Costa, 2016 .

Cost‐Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy

L. S. Miguel, C. Pereira, C. G. Pinto, 2017, Applied Health Economics and Health Policy.

[Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].

H. Marques, C. Pereira, S. Carvalho, 2010, Acta medica portuguesa.

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.

F. Barata, C. Pereira, H. Queiroga, 2008, Revista portuguesa de pneumologia.

PCN17 Indirect Comparison of the Efficacy of Erlotinib Versus Pemetrexed Plus Cisplatin as First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations

C. Pereira, J. Loff, M. Sanches, 2012 .